Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."
Why Novo Nordisk Stock Is Sinking This Week The global drugmaker is facing some headwinds related to tough competition.
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026.
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as the linchpin in the quest to develop cures for a myriad of debilitating diseases. This significant investment is poised to revolutionize how scientists approach genetic disorders, moving beyond [...]
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.
Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs.
Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for new doses.
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a higher counteroffer.
Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through.
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.
Novo Nordisk A/S-Spons ADR (NYSE:NVO) Embodies Affordable Growth Strategy Novo Nordisk (NVO) exemplifies affordable growth investing with strong expansion, reasonable valuation, high profitability, and a solid dividend.
Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump administration.
Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.
